Skip to main content
. Author manuscript; available in PMC: 2016 Nov 18.
Published in final edited form as: Bioconjug Chem. 2015 Jul 24;26(11):2243–2248. doi: 10.1021/acs.bioconjchem.5b00244

Figure 1.

Figure 1

(A) HER2-targeting monoclonal antibody trastuzumab in scFv-Fc format was engineered with or without selenocysteine (Sec) or cysteine (Cys) resulting in four different constructs, scFv-Fc, scFv-Fc-Sec, scFv-FcS396C, and scFv-FcS396C-Sec. Engineered Sec and Cys enabled site-specific modification of the antibody with dual modalities. (B) Structures of methylsulfone-ODA-fluorescein and biotin-ethylenediamine-iodoacetamide.